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In our previous paper, we reported that myeloid differential primary response protein (MyD88), a key adaptor in the signaling cascade of the
innate immune response, inhibits hepatitis B virus (HBV) replication. The MyD88 activated nuclear factor-kappaB (NF-κB) signaling pathway
and the intracellular upregulation of NF-κB signaling can induce an antiviral effect. Therefore, the association between the inhibition of HBV
replication by MyD88 and NF-κB activation was investigated further. The results show that NF-κB activation was moderately increased after
MyD88 expression. The strong activation of NF-κB by the IkappaB kinase complex IKKα/IKKβ dramatically suppressed HBV replication; the
MyD88 dominant negative mutant that abrogated NF-κB activity did not inhibit HBV replication. Furthermore, the IκBα dominant negative
mutant restored the inhibition of HBV replication by MyD88. These results support a role for NF-κB activation in the inhibition of HBV
replication and suggest a novel mechanism for the inhibition of HBV replication by MyD88 protein.
© 2007 Elsevier B.V. All rights reserved.Keywords: Hepatitis B virus; Myeloid differential primary response protein (MyD88); Antiviral activity; Nuclear factor-kappaB1. Introduction
Myeloid differential primary response protein (MyD88) has
been found to be the primary response gene in M1 myeloblastic
leukemia cells induced by IL-6 [1,2]. Studies have shown that
the MyD88 protein is a critical component in the signaling
cascade of the innate immune response. MyD88 transduces
signals from TIR-containing receptors to the death domain-
containing IL-1R-associated kinases (IRAKs), which lead to the
activation of downstream signaling, including NF-κB activa-
tion. In our previous study, we showed that MyD88 was
induced by IFN-α treatment, and that the expression of MyD88
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doi:10.1016/j.bbadis.2007.08.001reduction of total and cytoplasmic HBV RNAs at the
posttranscriptional level was noted [3]. Since NF-κB is
modestly activated by either IFN-α treatment or by MyD88
expression, and NF-κB activation has been shown to interfere
with viral replication [4], this suggests that the inhibition of
HBV replication by MyD88 may be mediated via NF-κB
activation.
NF-κB is a dimeric transcription factor that has important
roles in the regulation of numerous inducible genes involved
in the expression of inflammatory cytokines, cell survival,
and differentiation [5,6]. The NF-κB transcription factor can
be stimulated by various stimuli, including viral infections, as
well as cytokines such as TNF-α and interleukin-1β (IL-1β).
These stimuli typically activate the IκBα kinase complex
(IKK) that causes the phosphorylation of IκBα at conserved
serine residues, which in turn results in its degradation. The
degradation of IκBα releases NF-κB, which translocates to
the nucleus and initiates targeted gene transcription
[7–9].
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MyD88 protein can lead toNF-κB activation. The results strongly
suggest that the suppression of HBV replication by MyD88 is
dependent on NF-κB activity, since abrogation of NF-κB
activation by a dominant negative mutant of MyD88 or a
superrepressor form of IκBα abolished the suppressive effects of
MyD88 on HBV replication. All of these results support the
presence of a role for NF-κB signaling activation in the inhibition
of HBV replication.
2. Materials and methods
2.1. Cell culture and transfection
Huh7 and HepG2 cells were cultured in DMEM (Gibco-BRL, Grand
Island, NY, USA) supplemented with 10% FBS (Gibco-BRL), 2 mM
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco-BRL) at
37 °C in a humidified CO2 incubator. Huh7 cells at 70% confluency or HepG2
cells at 30% confluency were transfected with a 3:1 or 5:1 μl:μg ratio of
liposomes to DNA (Fugene reagent; Roche, Indianapolis, USA). All transfec-
tionswere performed using equal total amounts of plasmidDNAnormalizedwith
empty vector. The transfection efficiency was normalized by detecting the
activity of β-galactosidase in the cell lysates (β-Galactosidase Enzyme Assay
KitC; Promega, Madison, USA) after cotransfection with the pSV-β-galactosi-
dase (Promega) vector as the control.
2.2. Plasmids and chemicals
pcDNA-MyD88 encoding of the whole transcript of MyD88 has been
previously described [3]. Two mutant versions of MyD88 were constructed:
truncated M (1–151), encoding amino acids 1 to151 of N-terminal region, and
truncated M (152–296), encoding amino acids 152 to the C-terminal end.
pHBV3.8 contains a 1.2-copy of the HBV genome (kindly provided by Prof.
Wang Yuan, Institute of Biochemistry, Academia Sinica). Plasmid RcCMV-
IκBα-SR expresses a superrepressor form of IκBα in which serines 32 and 36
were mutated to alanine [10]. Plasmids pRc-β-actin-3HA-IKKα [11] and -IKKβ
[12] were provided by M. Karin, University of California, San Diego. The NF-
κB-dependent luciferase reporter plasmid pNF-κB-Luc was obtained from
Stratagene Corporation (La Jolla, CA, USA). To monitor the efficiency of
transfection, plasmid pRL-TK (Promega), which produces renilla luciferase,
was used as an internal control to monitor the efficiency of transfection.
SB203580 and PD98059 were obtained from Calbiochem (San Diego, CA,
USA).
2.3. Real-time PCR analysis of HBV replicative intermediate DNA
HBV replicative intermediate DNA in HBV core particles from transfected
cells was analyzed using quantitative real-time PCR as described by Lin et al.
[13,14]. Briefly, Huh7 or HepG2 cells were seeded onto 12-well plates at a
density of 2×105 cells/well. 48 h after transfection, the cells were washed twice
with chilled PBS and lysed in 600 μl lysing buffer (10 mmol/l Tris–HCl, pH 7.9,
1 mmol/l EDTA, 1% NP-40, 8% sucrose). After centrifugation at 12,000 rpm for
2 min at 4 °C to remove nuclei and debris, the supernatants were collected. To
normalize transfection efficiency, supernatants (50 μl) were used to detect the
activity of β-galactosidase; 6 μl 1 M magnesium acetate, 12 μl DNase I (5 mg/
ml), and 3 μl RNase A (20 mg/ml) were added to the supernatants, which were
subsequently incubated at 37 °C for 30 min to digest the remaining DNA and
RNA. After centrifugation at 12,000 rpm for 1 min, the supernatants were
collected. Next, 16 μl 0.5 M EDTA and 130 μl 35% PEG 8000 in 1.75 M NaCl
were added, and the mixture was kept on ice for 1 h to precipitate the core
particles. After spinning at 9000 rpm for 5 min, the pellets were re-suspended
and again digested with DNase I and then incubated at 37 °C for 10 min to
ensure full digestion of the remaining DNA that was used for transfection. The
re-suspended core particles were then digested with proteinase K, and nucleicacids were extracted and precipitated. At this stage, the DNA was further
digested withHpaII to remove plasmid DNA from Escherichia coli. Since DNA
methylation occurs at CCGG sequences, viral DNA derived from cells is
resistant to this enzyme [15]. A pair of primers flanking one of the six restriction
sites of HpaII was used for PCR to ensure that the amplified DNA product was
derived from the viral core particles within the transfected cells and was not
derived from the remaining plasmid HBV DNA used for transfection. A pair of
primers flanking nt 509 was used: HBVF, 5′-GCCCGTTTGTCCTCTAATTCC-
3′ (nt 468–488) and HBVR, 5′-GGGAAAGCCCTACGAACCACT-3′ (nt 698–
718). The PCR product was 251 bp. Each PCR was carried out in duplicate in a
20-μl volume using FastStart DNA Master SYBR Green I mixture (Roche) for
10 min at 95 °C for initial denaturing, followed by 40 cycles of 95 °C for 15 s,
56 °C for 15 s, and 72 °C for 30 s in a LightCycle system (Roche). Detection of
the fluorescent product was set at the last step of each cycle. To determine the
specificity of amplification, a melting curve analysis was applied to all final PCR
products after the cycling protocol. Results are representative of three in-
dependent experiments.
2.4. Western blot analysis
The cells were washed and harvested at 48 h post-transfection. Cell lysates
were separated by SDS-PAGE gel electrophoresis and blotted electrophoreti-
cally onto a nitrocellulose membrane (Roche). The membrane was blocked with
phosphate-buffered saline (PBS) containing 5% skim milk and then incubated
overnight with 1:2000 anti-IκBα (Sigma), 1:2000 anti-phospho-IκBα (Cell
signaling), 1:1000 anti-phospho-p38 (Cell signaling), 1:1000 anti-phospho-
ERK (Santa Cruz), 1:10000 anti-actin antibody (Sigma), then washed three
times in PBST (0.05% Tween 20 in PBS), and incubated with peroxidase-
conjugated secondary antibody (1:2000) (Amersham, Buckinghamshire,
England) for 1 h. After further washing with PBST, chemiluminescence
detection was carried out using ECL detection reagents (Amersham).
2.5. ELISA
The HBsAg and HBeAg levels in the supernatants obtained from HBV-
transfected Huh7 or HepG2 cells harvested 48 h post-transfection were
determined using a standard enzyme-linked immunosorbent assay (ELISA)
(Sino-American Biotech). Transfection efficiency was normalized by detecting
the activity of the β-galactosidase in the cell lysates. All experiments were
performed at least three times.
2.6. Immunofluorescence staining
Huh7 or HepG2 cells were seeded onto 12-well plates at a density of 2×105
cells/well. Each of the plasmids pCDNA-3.1, pcDNA-MyD88 (0.4 μg), and
RcCMV-IκBα-SR (0.2 μg) was transiently cotransfected with pHBV3.8
(0.2 μg) into cells. 48 h after transfection, cells were washed with PBS and
fixed with 3.7% paraformaldehyde in PBS for 10 min. The cells were
permeabilized with 0.2% Triton X-100 in PBS for 5 min at room temperature
and incubated in blocking buffer supplemented with 3% BSA (Sigma) for 1 h at
room temperature. HBcAg was stained with diluted (1:100) rabbit anti-HBcAg
antibody (Dako Co.); goat anti-rabbit-fluorescein isothiocyanate (FITC) or
rhodamine-conjugated anti-rabbit secondary antibody was used as the secondary
antibody. The nuclei of the cells were counterstained with 10 μg/ml 4′,6′-
diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO, USA). After
incubation with the secondary antibodies, the cells were visualized using a
confocal laser scanning microscope.
2.7. Luciferase activation assay
To measure report gene activation, Huh7 cells seeded onto 12-well plates
at density of 2×105 cells/well were transiently transfected with NF-κB-
dependent luciferase reporter plasmid pNF-κB-Luc (0.2 μg) alone, or together
with other plasmids. To monitor transfection efficiency, pRL-TK (0.02 μg)
was added to each well. The cells were lysed and analyzed for luciferase and
renilla luciferase activity (Promega). The results are reported as the
normalized mean±S.D.
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3.1. MyD88-mediated suppression of HBV replication is
independent of p38 MAPK and ERK1/2 signaling
Since expression of MyD88 activates NF-B and MAPK
family members, including ERK, p38, and JNK, we first
investigated whether the MAPK and ERKs play important roles
in the suppressive effect of MyD88 on HBV replication. Huh7
cells were transfected with MyD88-expressing plasmid. The
total IκBα and the phosphorylated active form of IκBa, p38, and
ERK1/2 were assessed with Western blot analysis. As shown in
Fig. 1A, in addition to the degradation of IκBα, increased
phosphorylation of IκBα, p38 and ERK1/2 was observed in
MyD88 transfected cells. To determine if these signaling
cascades are required for the suppression of HBV replication
by MyD88, SB203580, a specific inhibitor of p38 MAPK, and
PD98059, a specific inhibitor of ERK1/2, were used. Results
showed that, after the addition of SB203580, although phos-
phorylation of p38 was effectively blocked by SB203580 at
10 μM (Fig. 1D), the overexpression of MyD88 still signifi-
cantly suppressed HBV protein synthesis and DNA replication
(Fig. 1B). Similar results were obtained in the presence of
20 μMPD98059. As shown in Fig. 1C, the reduction in the HBV
HBsAg or HBeAg as well as core particle DNA levels by
MyD88 could not be altered by 20 μM PD98059, although
phosphorylation of ERK1/2 activated byMyD88was effectively
blocked by PD98059 at 20 μM (Fig. 1D). Taken together, these
results indicate that neither p38 MAPK nor ERK1/2 is required
for the MyD88-mediated antiviral effect against HBV.
3.2. NF-κB activation is essential for MyD88-mediated
suppression of HBV
In order to determine whether the NF-κB signaling pathway
is involved in the inhibition of HBV by MyD88, truncated
versions encoding the MyD88 NH2 terminal region [M (1–
151)] and the MyD88 dominant negative region [M (152–296)]
were constructed. Luciferase activity assay showed that, while
the expression of the full-length MyD88 (M-full) in Huh7 cells
resulted in the activation of NF-κB activity and M (1–151) was
still capable of inducing NF-κB activity, albeit to a lesser extent,
M (152–296) did not induce NF-κB activity (Fig. 2A).
To confirm if the NF-κB activity that is induced by MyD88
is essential for the inhibition of HBV replication, Huh7 and
HepG2 cells were transiently transfected with pHBV3.8 and M-
full, M (1–151), and M (152–296). Compared with M-full
transfected Huh7 cells, the expression of M (1–151) still led to a
reduction of viral protein synthesis and core particle-associated
HBV DNA (Fig. 2B). However, the expression of MyD88Fig. 1. Association of p38MAPK and ERKwith MyD88 in inhibition of HBVreplica
The expressions of IκBα and the phosphorylated form of IκBα, p38, and ERK1/2 i
SB203580 and PD98059 on MyD88-mediated suppression of HBV. Huh7 cells were
32 h after transfection, (B) the cells were treated with control solvent or 10 μM SB2
20 μM PD98059 (ERK inhibitor) for 16 h. The cell supernatants were analyzed for t
and analyzed using real-time PCR. (D) Part of the cells in the above studies were lyse
blotting.dominant negative M (152–296) did not have an inhibitory
effect on HBV replication. In HepG2 cells, similar results were
obtained (Fig. 2C).
3.3. Blockage of NF-κB activation abolishes MyD88-mediated
suppression of HBV
To block NF-κB activation, plasmid IκBα-SR was used.
Plasmid IκBα-SR, in which Ser32 and Ser36 residues critical for
phosphorylation by IKK are replaced by alanine and express the
superrepressor form of IκBα, was used. The Huh7 cells were
transfected with HBV DNA, plasmid M-full, or with a different
dose of plasmid IκBα-SR. Similar to the results described above,
after the expression ofMyD88, a reduction of 67%was observed
with HBeAg and a reduction of 78%with HBsAg was observed.
However, in the culture supernatants, the co-expression of IκBα-
SR led to a dose-dependent accumulation of 69%, 72%, and
96%, respectively, for HBeAg, and of 61%, 75%, and 92%,
respectively, for HBsAg (Fig. 3A). This indicates that MyD88
inhibition of HBV replication was disturbed. Immunostaining
was done to detect the presence of core protein in these cells. As
shown in Fig. 3C, the co-expression of MyD88 significantly
reduced core protein synthesis. However, the co-expression of
IκBα-SR dramatically restored the core protein level; the results
were consistent with IκBα-SR's effect on HBeAg and HBsAg.
The real-time PCR analysis of HBV replicative intermediate
DNA supported the above results (Fig. 3A). With HepG2 cells,
similar results were obtained (Fig. 3B, C).Taken together, these
results strongly indicate that the MyD88-mediated suppression
of HBV is dependent on NF-κB activation.
3.4. NF-κB activation alone is sufficient to inhibit
HBV replication
To further determine the role of NF-κB activation in the
inhibition of HBV by MyD88, we investigated whether the
activation of NF-κB alone could inhibit HBV replication. The
cotransfection of 0.1 μg of IKKα/IKKβ with the HBV genome
into Huh7 cells resulted in a 30% reduction of HBeAg and a
25% reduction of HBsAg (Fig. 4A). This reduction was even
more substantial if the amount of IKKα/IKKβ was increased to
0.4 μg; similar results were obtained when HBV core particle
DNA was measured (Fig. 4B). Thus, the above results further
support a role for NF-κB in the inhibition of HBV replication.
4. Discussion
Our previous studies revealed that MyD88, a key adaptor in
the signaling cascade of the innate immune response, can inhibit
hepatitis B virus (HBV) replication. NF-κB activation wastion. (A) Huh7 cells were transfected with 0.5 μg of empty vector or MyD88 (M).
n the total cell lysates were determined using Western blotting. (B, C) Effect of
transfected with pHBV3.8 (0.3 μg) and MyD88 (0.6 μg) or its parental vector.
03580 (pp38 inhibitor) for 16 h. (C) Cells were treated with control solvent or
he presence of HBsAg and HBeAg. HBV DNAwas isolated from core particles
d, and the phosphorylated form of p38 and ERK1/2 was analyzed using Western
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Fig. 2. Role of NF-κB in MyD88-mediated suppression of HBV. (A) Huh7 cells were transiently transfected with pNF-κB-Luc, empty vector, M-full, M (1–151), or
M (152–296). 48 h post-transfection, luciferase activities were measured. M-full, MyD88 full length; M (1–151), encoding MyD88 N-terminal region; M (152–296),
MyD88 dominant negative. (B, C) Effect of MyD88 expression on HBV protein synthesis and replication. pHBV3.8 was transfected into (B) Huh7 cells or (C) HepG2
cells with empty vector, M-full, M (1–151), or M (152–296). To detect core particle-associated HBV replicative intermediate DNA, Huh7 cells were harvested, and the
supernatants were analyzed for HBsAg and HBeAg expressions.
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lular upregulation of NF-κB signaling could induce an antiviral
effect. Therefore, in the present study, the association between
the inhibition of HBV replication by MyD88 and NF-κB
activation was further investigated. First, we found that the
suppression of the HBV RNA level was independent of the p38
MAPK and ERK1/2 signaling pathway (Fig. 1). Second,
overexpression of MyD88 triggers the activation of NF-κB
(Fig. 2A) and promotes nuclear translocation of the p65 subunit
of NF-κB (data not shown). Third, the expression of a mutant
form of IκBα, which abrogates the NF-κB activity that is
mediated byMyD88, abolished the suppressive effect ofMyD88
on HBV (Fig. 3). Fourth, the strong activation of NF-κB
signaling by the co-expression of IKKα/IKKβ alone was suf-
ficient to inhibit hepatitis B virus replication (Fig. 4).Taken
together, these results indicate that the inhibition of HBV
replication by MyD88 occurs through an NF-κB-dependent
pathway, and that the NF-κB signaling pathway functions as a
crucial mediator of MyD88's antiviral effect against HBV.NF-κB has been identified as a central regulator of host
immune and inflammatory responses. Studies have suggested
that the host utilizes NF-κB to trigger defense mechanisms
against viral pathogens. Mice deficient in different members of
the NF-κB family are more susceptible to infection [16–18].
Vaccinia virus A52R effectively mimics the effect of the
dominant-negative form of MyD88 and abrogates the IL-1-
mediated induction of NF-κB, which is important for resistance
to vaccinia virus [19]. TNF-alpha was reported to suppress
hepatitis B virus DNA replication by disrupting the formation or
the stability of cytoplasmic viral capsids through a pathway that
requires NF-κB activation [20]. Furthermore, NF-κB activation
was reported to drive an antiviral response in human cyto-
megalovirus (HCMV)-infected cells, and interferon-β was
identified as the responsible factor [4]. Our data show that
MyD88 has evolved the same strategies to exploit NF-κB
activation to dramatically inhibit HBV replication. Thus, the
triggering of NF-κB activation may be a common strategy
utilized by the host to activate the host immune response that
Fig. 3. Blockage of NF-κB activation abolishes MyD88-mediated suppression of HBV. (A) Huh7 cells were cotransfected with plasmids at the indicated doses.
(B) HepG2 cells were cotransfected with plasmids at the indicated doses. To detect core particle associated HBV replicative intermediate DNA, transfected cells were
harvested, and the supernatants were analyzed for HBsAg and HBeAg expressions. pSV-β-galactosidase was used to monitor transfection efficiency. Three
independent experiments were performed in duplicate. (C) Plasmid pHBV3.8 was transiently cotransfected into Huh7 or HepG2 cells with empty vector, pcDNA-
MyD88, or IκBα-SR. 48 h post-transfection, core protein staining was performed using rabbit anti-core polyclonal antibodies. HepG2.2.15, an HBV DNA stably
transfected hepatoblastoma cell line, was used as a positive control.
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that NF-κB activation can initiate the transcription of a number
of cellular antiviral genes. To identify the NF-κB-responsive
gene(s) that may play a key role in the antiviral action ofMyD88,
the levels of selected inflammatory and antiviral genes, in-
cluding IFN-β, IFN-γ, IL-6, TLR2, and TLR9, were analyzed in
MyD88-expressing Huh7 cells; however, no changes were de-
tected (data not shown). Further research is required to identify
the cellular genes that are activated by NF-κB to downregulate
HBV transcripts so that a more precise molecular understanding
of MyD88's antiviral action can be developed.
It has been reported that many viruses use activated NF-κB
for survival. For example, HBV X targets the NF-κB/IκBα
complex, causing the activation of NF-κB, which can promote
reverse transcription of pgRNA and viral DNA replication [21–
24]. However, in the present study, the activation of NF-κB was
found to be detrimental to HBV replication. It is possible that
the molecular mechanisms by which MyD88 or HBV activate
the NF-κB pathway are different. This may account for the
equilibrium that has been noted between the host and the HBVwith respect to NF-κB activation [25]; this issue should be
studied further.
In addition to activating NF-κB signaling, although co-
expression of MyD88 could lead to the activation of p38
MAPK and ERK (Fig. 1A), results showed that MyD88-
mediated suppression of HBV replication was independent of
p38 MAPK and ERK1/2 signaling (Fig. 1B, C). It has been
reported that there is correlation between MAPK, the ERK
signaling pathway and HBV replication [26,27]. For example,
the multifunctional HBx protein was found to be important
for viral infection. In the cytoplasm, HBx activates cellular
signaling pathways, such as Ras, Src, and c-Jun NH2-terminal
kinase (JNK), MAPK and phosphatidylinositol 3-kinase (PI-
3K) signal transduction pathways and that is thought to be
important for viral reverse transcription, transcriptional
activation, DNA replication and the HBV core assembly
[26,28–31]. It was also reported that HBx induces the
activation of p38 MAPK and the inhibition of p38 kinase
activity by SB203580-attenuated HBx-induced mitochondrial
clustering [23]. Besides, activated ERK1/2 has been shown to
Fig. 3 (continued ).
Fig. 4. The effect of NF-κB activation on HBV replication. Plasmid pHBV3.8
was transiently cotransfected into Huh7 cells with empty vector and different
doses of pRc-β-actin-3HA-IKKα and IKKβ to activate NF-κB. (A) 48 h after
transfection, culture supernatants were collected and analyzed for the expression
of HBsAg and HBeAg using standard immunoassays. (B) HBV replicative
intermediate DNAs were extracted from core particles and analyzed using real-
time PCR analysis. The bars show the mean±standard error of three
independent experiments performed in duplicate. ⁎Pb0.05, ⁎⁎Pb0.01.
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between their activation and the inhibitory effects of MyD88
on HBV replication was established. This could be due to the
differences in the degree of activation of ERK and MAPK
signaling by MyD88 and activated Ras [32].
It has been reported that poly(I·C) inhibits HBV replication
by inducing interferon-α/β [34] and study in transgenic mice
showed that HBV replication was significantly abolished by
the administration of ligands specific for TLR3, TLR4, TLR5,
TLR7, and TLR9 in an interferon-α/β-dependent manner [35],
all of which suggested that inhibition of HBV replication by
the TLR ligands was associated with the production of
interferon-α/β. Since IFN-α inducible MyD88 is a key adaptor
of TLR signaling, it is reasonable to test whether there was an
involvement of TLR signaling pathway in MyD88-mediated
anti-HBV replication. However, no significant production of
IFN-α/β as well as the activation of interferon signaling were
observed in MyD88 overexpressing cells (data not shown).
One possibility is that TLRs are not highly expressed in Huh7or HepG2 cells (data not shown). Another reason may be that
TLR ligands did not activate an antiviral program by targeting
the hepatocytes directly [35] and worthy to be further
investigated.
In conclusion, this study confirmed that MyD88 has in-
hibitory activity on HBV gene replication and further
demonstrated that the anti-HBV effect exerted by MyD88 is
mediated by the activation of the NF-κB signaling pathway.
Studies are ongoing to investigate the precise mechanism
involved in MyD88's antiviral effect against HBV, such as the
identification of inhibitory factor(s), which may lead to new
approaches for controlling chronic HBV infection.
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